Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Astellas Pharma Inc. (YPH.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
14.80+0.43 (+2.96%)
At close: 08:23PM CET
Advertisement

Astellas Pharma Inc.

2-5-1, Nihonbashi-Honcho
Chuo-Ku
Tokyo 103-8411
Japan
81 3 3244 3000
https://www.astellas.com

Sector(s)Healthcare
IndustryDrug Manufacturers—General
Full Time Employees14,522

Key Executives

NameTitlePayExercisedYear Born
Mr. Kenji Yasukawa Ph.D.Pres, CEO & Chairman2.11MN/A1960
Mr. Naoki Okamura BScExec. VP, Chief Strategy Officer & Representative Director1.09MN/AN/A
Minoru KikuokaCFO & Sr. Managing Exec. OfficerN/AN/AN/A
Nobue YasudaGen. Mang. of Fin. & Accounting DepartmentN/AN/AN/A
Mr. Yoshitsugu Shitaka Ph.D.Chief Scientific Officer & Sr. Managing Exec. OfficerN/AN/AN/A
Ms. Catherine B. LevittGen. CounselN/AN/AN/A
Mr. Katsuyoshi SugitaChief People Officer and Chief Ethics & Compliance OfficerN/AN/AN/A
Mr. Stig OgataVP of Corp. CommunicationsN/AN/AN/A
Ms. Collette TaylorSr. VP of HRN/AN/A1963
Chihiro YokotaSr. Corp. Exec. and Head of Japan/Asia Devel., Devel.N/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

Corporate Governance

Astellas Pharma Inc.’s ISS Governance QualityScore as of December 1, 2022 is 1. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 5; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement